Abstract
There is active scientific debate about the nature of addiction as a mental disorder, but with comparatively little discussion of nosology itself. To contribute to the ongoing dialogue, this review provides a concise history of the formal medical diagnoses used to define addiction clinically and vanguard contemporary perspectives. The history of addiction as a medical diagnosis starts at the beginning of the 20th century in the first International Classification of Diseases (ICD) and was present in 1953 in the first edition of the Diagnostic and Statistical Manual (DSM). Across iterations of both systems, the evolving nosology can be broadly divided into three epochs, an early primeval period (1900–1948), reflecting coarse definitions subsumed within personality disorder; a phenomenological period (1948–1980), reflecting descriptive definitions; and an empirically-informed period (1980 to the present), comprising operational definitions of polythetic syndromes, increasingly informed by empirical findings. Contemporary priorities suggest an emerging fourth epoch, prioritizing a diagnostic nomological network of objective etiologically-informed tests via, for example, the Research Domain Criteria (RDoC) and Addictions Neuroclinical Assessment (ANA) frameworks. Both RDoC and ANA focus on using objective mechanistic indicators to decrease subjectivity in diagnosis and increase alignment between etiology and diagnosis. Next-generation diagnostic approaches are anticipated to enhance incisiveness in psychiatric diagnosis and in turn improve clinical outcomes. Tracing the vicissitudes of addiction nosology over the past century reveals an evolution that is both more humane and scientific, from moral weakness and personality defect toward diagnostic definitions and practices that are grounded in empirical evidence.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 13 print issues and online access
$259.00 per year
only $19.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout


Similar content being viewed by others
Notes
The DSM naming convention shifted from Roman numerals to Arabic numbering between DSM-IV and DSM-5 to be clearer about the numeric value and avoid interpretations of DSM-letter-V.
References
Szasz TS. The myth of mental illness. Am Psychol. 1960;15:113–8.
Wakefield JC. Diagnostic issues and controversies in DSM-5: return of the false positives problem. Annu Rev Clin Psychol. 2016;12:105–32.
Leshner AI. Addiction is a brain disease, and it matters. Science. 1997;45–7. www.sciencemag.org.
Heilig M, MacKillop J, Martinez D, Rehm J, Leggio L, Vanderschuren LJMJ. Addiction as a brain disease revised: why it still matters, and the need for consilience. Neuropsychopharmacology. 2021;46:1715–23.
Wiens TK, Walker LJ. The chronic disease concept of addiction: Helpful or harmful?. Addictn Res Theory. 2015;23:309–21.
Peele S. People control their addictions: no matter how much the “chronic” brain disease model of addiction indicates otherwise, we know that people can quit addictions – with special reference to harm reduction and mindfulness. Addictn Behav Rep. 2016;4:97–101. https://w-ww.sciencedirect.com/science/article/pii/S235285321630013X?via%3Dihub.
Field M, Heather N, Wiers RW. Indeed, not really a brain disorder: implications for reductionist accounts of addiction. Behav Brain Sci. 2019;42.
Cunningham JA. Addiction: many factors contribute. Nature. 2014;507:40. https://www.nature.com/articles/507040d.
Brown J, Michie S, Raupach T, West R. Animal Farm must give way to doublethink when studying addiction. Addiction. 2014;109:1214–5. https://doi.org/10.1111/add.12553.
Heim D. Addiction: not just brain malfunction. Nature. 2014;507:40. http://www.nature.com/articles/507040e.
Kaye K. De-Medicalizing addiction: Toward biocultural understandings. Adv Med Socio. 2012;14:27–51.
Suissa AJ. Medicalization and addictions: Markers and Psychosocial Issues. Canadian Social Work Review / Revue Canadienne de Service Social. 2009;26:43–58. http://www.jstor.org/stable/41669901.
Chau LW, Erickson M, Vigo D, Lou H, Pakhomova T, Winston ML, et al. The perspectives of people who use drugs regarding short term involuntary substance use care for severe substance use disorders. Int J Drug Policy. 2021;97:103208. https://www.sciencedirect.com/science/article/pii/S0955395921001067.
Frank D. I was not sick and i didn’t need to recover”: methadone maintenance treatment (MMT) as a refuge from criminalization. Subst Use Misuse. 2018;53:311–22. https://doi.org/10.1080/10826084.2017.1310247.
Acuff SF, MacKillop J, Murphy JG. A contextualized reinforcer pathology approach to addiction. Nat Rev Psychol. 2023;2:309–23. https://www.nature.com/articles/s44159-023-00167-y.
Witkiewitz K, Tucker JA. Whole person recovery from substance use disorder: a call for research examining a dynamic behavioral ecological model of contexts supportive of recovery. Addictn Res Theory. 2024 https://doi.org/10.1080/16066359.2024.2329580.
Rosenthal RJ, Faris SB. The etymology and early history of ‘addiction. Addictn Res Theory. 2019;27:437–49.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders 5. American Psychiatric Association; 2013.
World Health Organization. International Classification of Diseases. 2019.
Katcher BS. Benjamin Rush’s educational campaign against hard drinking. Am J Public Health. 1993;83:273. https://pmc.ncbi.nlm.nih.gov/articles/PMC1694575/.
Institute of Medicine (US) Committee on Opportunities in Drug Abuse Research. Pathways of Addiction: Opportunities in Drug Abuse Research. Washington (DC): National Academies Press (US); 1996. B, Drug Abuse Research in Historical Perspective. Available from: https://www.ncbi.nlm.nih.gov/books/NBK232965/
Kielhorn FW. The history of alcoholism: Brühl-Cramer’s concepts and observations. Addiction. 1996;91:121–8. https://doi.org/10.1046/j.1360-0443.1996.91112114.x.
Crocq MA. Historical and cultural aspects of man’s relationship with addictive drugs. Dialogues Clin Neurosci. 2007;9:355. https://pmc.ncbi.nlm.nih.gov/articles/PMC3202501/.
White WL. Slaying the dragon: the history of addiction treatment and recovery in America. In: Slaying the dragon: the history of addiction treatment and recovery in America. 2nd ed. Chestnut Health Systems; 1998 https://archive.org/details/slayingdragonhis00whit/page/22/mode/2up?view=theater.
Office of the Surgeon General ASForces. Nomenclature of psychiatric disorders and reactions. War Department Technical Bulletin, Medical 203;1946. https://pubmed.ncbi.nlm.nih.gov/10902951/.
Statistical Manual for the Use of Institutions for the Insane. (New York: The National Committee for Mental Hygiene, Bureau of Statistics, 1918.). Am J Psychiatry. 1918;75:301. https://doi.org/10.1176/ajp.75.2.301.
Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry. 1970;126:983–7.
Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G, Munoz R, et al. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 1972;26:57–63. http://archpsyc.jamanetwork.com/.
Edwards G, Gross MM. Alcohol dependence: provisional description of a clinical syndrome. Br Med J. 1976;1:1058–61. https://about.jstor.org/terms.
Moriyama IM, Loy RM, Robb-Smith AHT, Rosenberg HM, Hoyert DL, National Center for Health Statistics (U.S.). History of the statistical classification of diseases and causes of death. 2011. CDC National Centre for Health Statistics
Hird TA. The morphia habit [Edinburgh]. University of Edinburgh; 1882.
Bertillon J. International classification of causes of sickness and death. Palo Alto; 1909 https://books.google.ca/books?id=iBR9entwjg0C&newbks=1&newbks_redir=0&dq=bertillon+classification&pg=PA1&redir_esc=y#v=onepage&q&f=false.
American Public Health Association & Conference Of State And Provincial Boards Of Health Of North America. The Bertillon classification of causes of death. [Lansing Mich. R. Smith print. co](1899) Library of Congress, https://www.loc.gov/item/01005126/.
East WN. Mental defectiveness and alcohol and drug addiction. Br J Inebr. 1932;29:149–66.
Chopra RN, Bose JP. Psychological aspects of opium addiction. Ind Med Gaz. 1931;663–6.
Lindesmith AR. A sociological theory of drug addiction. Am J Sociol. 1938;43:593–613. https://www.jstor.org/stable/2768486.
Hart B. Discussion on the aetiology of alcoholism. Proceedings of the Royal Society of Medicine. 1928;21:1341–60.
Spitzer RL, Fleiss JL. A re-analysis of the reliability of psychiatric diagnosis. Br J Psychiatry. 1974;123:341–7.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 1952. Washington, DC: Author
Lassiter PS, Culbreth JR. Historical perspectives and the moral model: theory and practice of addiction counseling. In: Theory and practice of addiction counseling. SAGE Publications, Inc.; 2018. p. 27–46.
Juchem CM, Bendau A, Bandurski LC, Reich NJ, Baumgardt S, Asselmann E. Personality changes related to presence and treatment of substance use (disorders): a systematic review. Psychol Med. 2024;54:1905–29. https://www.cambridge.org/core/journals/psychological-medicine/article/personality-changes-related-to-presence-and-treatment-of-substance-use-disorders-a-systematic-review/A3674BD132B366F0101C536EB053DE20.
Roberts BW, Luo J, Briley DA, Chow PI, Su R, Hill PL. A systematic review of personality trait change through intervention. Psychol Bull. 2017;143:117–41. https://pubmed.ncbi.nlm.nih.gov/28054797/.
Kotov R, Gamez W, Schmidt F, Watson D. Linking “Big” personality traits to anxiety, depressive, and substance use disorders: a meta-analysis. Psychol Bull. 2010;136:768–821. https://pubmed.ncbi.nlm.nih.gov/20804236/.
Krueger RF, Bezdjian S. Enhancing research and treatment of mental disorders with dimensional concepts: toward DSM-V and ICD-11. World Psychiatry. 2009;8:3–6.
Regier DA, Narrow WE, Clarke DE, Kraemer HC, Kuramoto SJ, Kuhl EA, et al. DSM-5 field trials in the United States and Canada, part II: Test-retest reliability of selected categorical diagnoses. Am J Psychiatry. 2013;170:59–70. https://doi.org/10.1176/appi.ajp.2012.12070999.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders fifth edition text revision. 5th-TR ed. APA; 2022.
Mayes R, Horwitz AV. DSM-III and the revolution in the classification of mental illness. J Hist Behav Sci. 2005;41:249–67.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders III-R. 1987. Washington D.C. (Author)
O’Brien CP, Volkow N, Li TK. What’s in a word? Addiction versus dependence in DSM-V. Am J Psychiatry. 2006;163:764–5.
Hasin DS, O’Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, et al. DSM-5 criteria for substance use disorders: Recommendations and rationale. Am J Psychiatry. 2013;170:834–51.
First MB, Gaebel W, Maj M, Stein DJ, Kogan CS, Saunders JB, et al. An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5. World Psychiatry. 2021;20:34–51. https://doi.org/10.1002/wps.20825.
Reed GM, First MB, Kogan CS, Hyman SE, Gureje O, Gaebel W, et al. Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry. 2019;18:3. https://pmc.ncbi.nlm.nih.gov/articles/PMC6313247/.
Fink DS, Shmulewitz D, Mannes ZL, Stohl M, Livne O, Wall M, et al. Construct validity of DSM-5 cannabis use disorder diagnosis and severity levels in adults with problematic substance use. J Psychiatr Res. 2022;155:387–94.
Reed GM, Correia JM, Esparza P, Saxena S, Maj M. The WPA-WHO Global Survey of Psychiatrists’ attitudes towards mental disorders classification. World Psychiatry. 2011;10:118. https://pmc.ncbi.nlm.nih.gov/articles/PMC3105474/.
Walton KE, Ormel J, Krueger RF. The dimensional nature of externalizing behaviors in adolescence: evidence from a direct comparison of categorical, dimensional, and hybrid models. J Abnorm Child Psychol. 2011;39:553–61.
Haslam N, Holland E, Kuppens P. Categories versus dimensions in personality and psychopathology: a quantitative review of taxometric research. Psychol Med. 2012;42:903–20.
Garber ML, Taisir R, Costello J, MacKillop J. Taxonicity of cannabis use disorder: findings from a large community sample and an inpatient clinical sample. J Psychopathol Clin Sci. 2025;134:790–8.
Martin CS, Steinley DL, Vergés A, Sher KJ. Letter to the Editor: The proposed 2/11 symptom algorithm for DSM-5 substance-use disorders is too lenient. Psychol Med. 2011;41:2008–10.
Mcqueen J, Howe TE, Allan L, Mains D, Hardy V. Brief interventions for heavy alcohol users admitted to general hospital wards. Cochrane Database Syst Rev. 2011;2011. https://doi.org/10.1002/14651858.CD005191.pub3/full.
Wilk AI, Jensen NM, Havighurst TC. Meta-analysis of randomized control trials addressing brief interventions in heavy alcohol drinkers. J Gen Intern Med. 1997;12:274–83. https://doi.org/10.1007/s11606-006-5063-z12:5.
Brown TA, Campbell LA, Lehman CL, Grisham JR, Mancill RB. Current and lifetime comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. J Abnorm Psychol. 2001;110:585–99.
Kessler RC, Tat Chiu W, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62:617–27.
Westen D. Prototype diagnosis of psychiatric syndromes. World Psychiatry. 2012;11:16–21.
Vergés A, Lee MR, Martin CS, Trull TJ, Martens MP, Wood PK, et al. Not all symptoms of alcohol dependence are developmentally equivalent: implications for the false-positives problem. Psychol Addic. Behav. 2021;35:444–57.
Maccorquodale K, Meehl PE. On a distinction between hypothetical constructs and intervening variables. Psychol Rev. 1948;55:95–107.
DeFife JA, Peart J, Bradley B, Ressler K, Drill R, Westen D. Validity of prototype diagnosis for mood and anxiety disorders. JAMA Psychiatry. 2013;70:140–8.
Westen D, Shedler J, Bradley R. A prototype approach to personality disorder diagnosis. Am J Psychiatry. 2006;163:846–56.
Kotov R, Waszczuk MA, Krueger RF, Forbes MK, Watson D, Clark LA, et al. The hierarchical taxonomy of psychopathology (HiTOP): a dimensional alternative to traditional nosologies. J Abnorm Psychol. 2017;126:454–77.
Kotov R, Krueger RF, Watson D, Cicero DC, Conway CC, Deyoung CG, et al. The Hierarchical Taxonomy of Psychopathology (HiTOP): a quantitative nosology based on consensus of evidence. Annu Rev Clin Psychol. 2021;17:83–108. https://doi.org/10.1146/annurev-clinpsy-081219-.
Waldman ID, Poore HE, Luningham JM, Yang J. Testing structural models of psychopathology at the genomic level. World Psychiatry. 2020;19:350–9.
Ringwald WR, Forbes MK, Wright AGC. Meta-analysis of structural evidence for the Hierarchical Taxonomy of Psychopathology (HiTOP) model. Psychol Med. 2021;53:533–46.
Haeffel GJ, Jeronimus BF, Fisher AJ, Kaiser BN, Weaver LJ, Vargas I, et al. The Hierarchical Taxonomy of Psychopathology (HiTOP) is not an improvement over the DSM. Clin Psychol Sci. 2022;10:285–90.
Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748–51.
Sanislow CA, Pine DS, Quinn KJ, Kozak MJ, Garvey MA, Heinssen RK, et al. Developing constructs for psychopathology research: research domain criteria. J Abnorm Psychol. 2010;119:631–9.
Lempert KM, Steinglass JE, Pinto A, Kable JW, Simpson HB. Can delay discounting deliver on the promise of RDoC? Psychol Med. 2019;49:190–9.
Owens MM, Gray JC, Amlung MT, Oshri A, Sweet LH, MacKillop J. Neuroanatomical foundations of delayed reward discounting decision making. NeuroImage. 2017;161:261–70.
Owens MM, Syan SK, Amlung M, Beach SRH, Sweet LH, MacKillop J. Functional and structural neuroimaging studies of delayed reward discounting in addiction: a systematic review. Psychol Bull. 2019;145:141–64.
Sanchez-Roige S, Fontanillas P, Elson SL, Pandit A, Schmidt EM, Foerster JR, et al. Genome-wide association study of delay discounting in 23,217 adult research participants of European ancestry. Nat Neurosci. 2018;21:16–20.
MacKillop J, Amlung MT, Few LR, Ray LA, Sweet LH, Munafò MR. Delayed reward discounting and addictive behavior: a meta-analysis. Psychopharmacology. 2011;216:305–21.
Amlung M, Marsden E, Holshausen K, Morris V, Patel H, Vedelago L, et al. Delay discounting as a transdiagnostic process in psychiatric disorders: a meta-analysis. JAMA Psychiatry. 2019;76:1176–86.
Jackson JNS, Mackillop J. Attention-deficit hyperactivity disorder and monetary delay discounting: a meta-analysis of case-control studies. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016;1:316–25. https://doi.org/10.1016/j.bpsc.2016.01.007.
Steinglass JE, Lempert KM, Choo TH, Kimeldorf MB, Wall M, Walsh BT, et al. Temporal discounting across three psychiatric disorders: anorexia nervosa, obsessive compulsive disorder, and social anxiety disorder. Depress Anxiety. 2016;34:463–70.
Lilienfeld SO. The Research Domain Criteria (RDoC): an analysis of methodological and conceptual challenges. Behav Res Ther. 2014;62:129–39.
Kwako LE, Momenan R, Litten RZ, Koob GF, Goldman D. Addictions neuroclinical assessment: a neuroscience-based framework for addictive disorders. Biol Psychiatry. 2016;80:179–89.
Votaw VR, Pearson MR, Stein E, Witkiewitz K. The addictions neuroclinical assessment negative emotionality domain among treatment-seekers with alcohol use disorder: construct validity and measurement invariance. Alcohol Clin Exp Res. 2020;44:679–88.
Votaw VR, Boness CL, Stein ER, Watts AL, Sher KJ, Witkiewitz K. Examining the validity of the addictions neuroclinical assessment domains in a crowdsourced sample of adults with current alcohol use. Exp Clin Psychopharmacol. 2023;32:68–83.
Nieto SJ, Ray LA. Applying the addictions neuroclinical assessment to derive neurofunctional domains in individuals who use methamphetamine. Behav Brain Res. 2022;427:113876.
Nieto SJ, Grodin EN, Green RJ, Ray LA. Evaluation of the Addictions Neuroclinical Assessment (ANA) framework through deep phenotyping of problem drinkers. Drug Alcohol Depend. 2021;221.
Gunawan T, Luk JW, Schwandt ML, Kwako LE, Vinson T, Horneffer Y, et al. Factors underlying the neurofunctional domains of the Addictions Neuroclinical Assessment assessed by a standardized neurocognitive battery. Transl Psychiatry. 2024;14:1–12. http://www.nature.com/articles/s41398-024-02987-9.
Meisel MK, Clifton AD, MacKillop J, Goodie AS. A social network analysis approach to alcohol use and co-occurring addictive behavior in young adults. Addictive Behav. 2015;51:72–9. http://pubmed.ncbi.nlm.nih.gov/26240940/.
Falade-Nwulia O, Felsher M, Kidorf M, Tobin K, Yang C, Latkin C. The impact of social network dynamics on engagement in drug use reduction programs among men and women who use drugs. J Subst Abus Treat. 2021;137. 108713. https://pmc.ncbi.nlm.nih.gov/articles/PMC9086095/.
Christakis NA, Fowler JH. The collective dynamics of smoking in a large social network. N Engl J Med. 2008;358:2249–58. http://pubmed.ncbi.nlm.nih.gov/18499567/.
Acuff SF, MacKillop J, Murphy JG. Integrating behavioral economic and social network influences in understanding alcohol misuse in a diverse sample of emerging adults. Alcohol Clin Exp Res. 2020;44:1444–55. https://doi.org/10.1111/acer.14351.
Levitt EE, Singh D, Clifton A, Stout R, Sweet L, Kelly JF, et al. Diagnostic discrimination of social network indicators in alcohol use disorder: initial examination using high-resolution and brief assessments. Psychol Addict Behav. 2024;38. https://pubmed.ncbi.nlm.nih.gov/38635199/.
Rehm J, Marmet S, Anderson P, Gual A, Kraus L, Nutt DJ, et al. Defining substance use disorders: Dowe really need more than heavy use?. Alcohol Alcohol. 2013;48:633–40.
Bradley KA, Rubinsky AD. Why not add consumption measures to current definitions of substance use disorders? Commentary on rehm et al. “defining substance use disorders: Dowe really need more than heavy use?. Alcohol Alcohol. 2013;48:642–3.
Garber ML, Samokhvalov A, Chorny Y, LaBelle O, Rush B, Costello J, et al. Diagnostic validity of drinking behaviour for identifying alcohol use disorder: findings from a representative sample of community adults and an inpatient clinical sample. Addiction. 2025;120. http://www.ncbi.nlm.nih.gov/pubmed/40162686.
MacKillop J, Agabio R, Feldstein Ewing SW, Heilig M, Kelly JF, Leggio L, et al. Hazardous drinking and alcohol use disorders. Nat Rev Dis Primers. 2022;8. https://pubmed.ncbi.nlm.nih.gov/36550121/.
Scott J, Leboyer M, Hickie I, Berk M, Kapczinski F, Frank E, et al. Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. Br J Psychiatry. 2013;202:243–5.
Patel A, West HJ. What does my stage of cancer mean? JAMA Oncol. 2020;6:1308.
Kapczinski F, Dias VV, Kauer-Sant’Anna M, Frey BN, Grassi-Oliveira R, Colom F, et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother. 2009;9:957–66.
McLellan AT, Koob GF, Volkow ND. Preaddiction—a missing concept for treating substance use disorders. JAMA Psychiatry. 2022;79:749–51. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2793694.
Boness CL, Kataria K, Morris J. Should we embrace the term ‘preaddiction’? Neuropsychopharmacology. 2023;49:495. https://pmc.ncbi.nlm.nih.gov/articles/PMC10789777/.
Volkow ND. Stigma and the toll of addiction. New Engl J Med. 2020;382:1289–90.
Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. Int J Drug Policy. 2010;21:202–7.
Saitz R. International statement recommending against the use of terminology that can stigmatize people. J Addiction Med. 2016;10:1–2.
Funding
Funding to support this work was provided by the Peter Boris Chair in Addictions Research, and a Canada Research Chair in Translational Addiction Research (CRC-2020-00170).
Author information
Authors and Affiliations
Contributions
Both authors made significant contributions to this work. The project was conceptualized by both authors. J.M. received funding which supported this project. The original draft of the manuscript was written by M.L.G. and was substantially revised by both authors. All authors approved the final version of the manuscript and are accountable for all aspects of the work.
Corresponding author
Ethics declarations
Competing interests
JM is a principal in BEAM Diagnostics, Inc. and MLG has no potential conflicts of interest to disclose.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Garber, M.L., MacKillop, J. The nosology of addiction as a medical condition: a concise history and review of contemporary perspectives. Neuropsychopharmacol. 51, 373–382 (2026). https://doi.org/10.1038/s41386-025-02257-2
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41386-025-02257-2


